profit from every $100 of sales.
$0$100
Exagen
$4.13-6.35% today
-55.8% in 1 year
1-year low $2.651-year high $9.35
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Exagen sold, what it kept, and what it did with the cash.
Sales went from $45.6 million in 2022 to $66.6 million in 2025, with -$20.0 million of profit last year.
SalesProfit
Exagen vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Exagen | No profit yet | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Exagen's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 46 | 53 | 56 | 67 | |
| 21 | 29 | 33 | 39 | |
| -41 | -23 | -14 | -14 | |
| -44 | -19 | -11 | -13 | |
| -47 | -24 | -15 | -20 | |
| -2.77 | -1.34 | -0.83 | -0.93 | |
| 46.9% | 56.1% | 59.5% | 58.3% | |
| -89.0% | -43.5% | -24.5% | -21.1% | |
| -104.0% | -45.1% | -27.2% | -30.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 86 | 57 | 45 | 58 |
| Cash | 62 | 36 | 22 | 32 |
| Total debt | 35 | 23 | 23 | 26 |
| Total liabilities | 44 | 34 | 35 | 41 |
| 42 | 23 | 10 | 17 | |
| 17 | 18 | 18 | 22 | |
| -46.0% | -36.7% | -31.0% | -28.5% | |
| -111.6% | -104.4% | -158.4% | -114.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -32 | -14 | -13 | -14 | |
| 4 | 1 | 1 | 1 | |
| -36 | -15 | -14 | -14 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 5 | 4 | 2 | 2 |
Valuation
- –
- –
- –
- 6.2×
- 1.6×
- –
- –
- -13.5%
- -18.9%
- 0.0%
Profitability
- 58.3%
- -21.1%
- -30.0%
- -23.3%
- -33.3%
- -54.0%
- -113.5%
- -38.8%
- -35.8%
- 9.5%
Growth
- +13.5%
- –
- −3.4%
- –
- +7.8%
Financial health
- -0.5×
- 0.34
- 9.3%
- -5.6×
- 3.47
- 3.47
- 1.32
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 946
Bottom 12%of 872
Top 43%of 868
Bottom 8%of 986
What analysts expect
- Average price target
- $9.00
- Range
- $8.00 – $10.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.17 | -0.24 | +29.2% |
| Mar 10, 2026 | -0.20 | -0.20 | +0.0% |
| Nov 4, 2025 | -0.19 | -0.13 | −46.2% |
| Jul 29, 2025 | -0.18 | -0.18 | +0.0% |
| May 5, 2025 | -0.20 | -0.20 | +0.0% |
| Mar 11, 2025 | -0.20 | -0.27 | +25.9% |
| Nov 12, 2024 | -0.28 | -0.30 | +6.7% |
| Aug 5, 2024 | -0.16 | -0.36 | +55.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
38No pass
Philip Fisher
40No pass
Peter Lynch
48No pass
Joel Greenblatt
0No pass
Charlie Munger
32No pass
Terry Smith
35No pass
Questions about Exagen
Is Exagen a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Exagen AI analysis
What does Exagen do?
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It is in Medical - Diagnostics & Research.
Does Exagen pay a dividend?
No. Exagen does not pay a dividend at the moment.
Is Exagen stock halal?
Questionable. Exagen sits in a grey zone: its cash and confirmed interest-bearing investments are 31% of its market value, between 30% and 33%. How we check
How has Exagen stock done over the past year?
Down 55.8% over the past twelve months, to $4.13. It traded between $2.65 and $9.35 and is 55.8% below its high.
Who are Exagen's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Exagen's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.